REGENXBIO (NASDAQ:RGNX) Sets New 52-Week Low at $11.75

REGENXBIO Inc. (NASDAQ:RGNXGet Free Report)’s share price reached a new 52-week low on Monday . The stock traded as low as $11.75 and last traded at $11.76, with a volume of 341308 shares traded. The stock had previously closed at $12.41.

Analyst Ratings Changes

RGNX has been the topic of several research analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $45.00 price target on shares of REGENXBIO in a report on Wednesday, February 21st. SVB Leerink raised REGENXBIO from a “market perform” rating to an “outperform” rating and set a $37.00 target price on the stock in a research note on Wednesday, March 6th. Stifel Nicolaus reissued a “buy” rating and issued a $40.00 target price on shares of REGENXBIO in a research note on Friday, April 12th. Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Thursday, March 7th. Finally, HC Wainwright increased their target price on REGENXBIO from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, May 15th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and a consensus price target of $38.58.

Read Our Latest Stock Report on REGENXBIO

REGENXBIO Stock Performance

The firm’s 50-day simple moving average is $15.46 and its 200-day simple moving average is $17.30.

REGENXBIO (NASDAQ:RGNXGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.10). REGENXBIO had a negative net margin of 299.96% and a negative return on equity of 70.72%. The business had revenue of $15.60 million for the quarter, compared to analysts’ expectations of $23.52 million. During the same quarter in the previous year, the company earned ($1.53) earnings per share. The business’s quarterly revenue was down 18.3% on a year-over-year basis. As a group, equities research analysts anticipate that REGENXBIO Inc. will post -3.9 EPS for the current year.

Insider Transactions at REGENXBIO

In other news, CEO Kenneth T. Mills sold 15,000 shares of the stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $15.81, for a total transaction of $237,150.00. Following the completion of the sale, the chief executive officer now directly owns 408,035 shares in the company, valued at $6,451,033.35. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 13.13% of the stock is currently owned by company insiders.

Institutional Trading of REGENXBIO

A number of institutional investors have recently modified their holdings of the company. PNC Financial Services Group Inc. lifted its holdings in REGENXBIO by 73.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after buying an additional 746 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in REGENXBIO in the first quarter worth about $56,000. Annandale Capital LLC purchased a new stake in REGENXBIO in the third quarter worth about $60,000. Headlands Technologies LLC lifted its holdings in REGENXBIO by 276.8% in the first quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock worth $81,000 after buying an additional 2,812 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in REGENXBIO by 352.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,093 shares of the biotechnology company’s stock worth $91,000 after buying an additional 3,968 shares during the period. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

About REGENXBIO

(Get Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Featured Articles

Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.